PMC:7696151 / 69130-69299 JSONTXT

{"project":"LitCovid-PubTator","denotations":[{"id":"1989","span":{"begin":12,"end":26},"obj":"Chemical"},{"id":"1990","span":{"begin":43,"end":46},"obj":"Chemical"},{"id":"1991","span":{"begin":133,"end":140},"obj":"Chemical"}],"attributes":[{"id":"A1989","pred":"tao:has_database_id","subj":"1989","obj":"MESH:D012460"},{"id":"A1990","pred":"tao:has_database_id","subj":"1990","obj":"MESH:D006886"},{"id":"A1991","pred":"tao:has_database_id","subj":"1991","obj":"MESH:D019788"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":" 2 g/day of sulphasalazine, 5 mg/kg/day of HCQ and a low dose of oral PRD (under 10 mg/day) is associated with a reduction of 30% in 18F-FDG uptake measures on PET imagi"}